ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

27 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

20 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

07 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

31 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

19 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

10 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

05 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

02 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

20 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

09 9 2023 20:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

31 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

14 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

07 8 2023 16:45:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

02 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

19 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

20 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

13 6 2023 08:42:03 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

03 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

15 5 2023 16:05:01 提供 Nasdaq GlobeNewswire